Lunesta vs Belsomra: Switching Between Eszopiclone and Suvorexant

How These Two Drugs Work Differently

Lunesta and Belsomra treat the same condition through opposing pharmacologic strategies. Understanding this difference is the foundation for deciding which drug to use and how to transition between them.

Eszopiclone (Lunesta) is the S-isomer of zopiclone and binds to the GABA-A receptor complex, enhancing inhibitory neurotransmission across the brain. This mechanism is shared with benzodiazepines, zolpidem, and zaleplon, though eszopiclone has a longer half-life (approximately 6 hours) than zolpidem (2.5 hours). The result is both sleep-onset and sleep-maintenance benefit, confirmed across a 6-month double-blind trial by Krystal et al. (2003) that enrolled 788 adults with chronic insomnia [1].

Suvorexant (Belsomra) takes the opposite approach. Rather than amplifying inhibition, it blocks orexin-A and orexin-B receptors (OX1R and OX2R), which are neuropeptides responsible for promoting and sustaining wakefulness. By silencing this "stay awake" signal, suvorexant permits the brain's natural sleep architecture to take over. Herring et al. (2014) demonstrated this mechanism across two Phase III trials (STUDY 028 and STUDY 029) enrolling over 3,000 patients with primary insomnia [2].

The clinical consequence of this mechanistic split is significant. GABA modulators like eszopiclone tend to alter sleep architecture by increasing Stage 2 (N2) sleep at the expense of slow-wave sleep, while orexin antagonists appear to preserve a more physiologic distribution of sleep stages, including REM sleep. A 2015 polysomnographic analysis published in Sleep Medicine confirmed that suvorexant increased REM sleep duration by 6 to 10 minutes compared with placebo [3].

Efficacy: Which Drug Performs Better?

No head-to-head randomized trial has directly compared eszopiclone with suvorexant. Any comparison must rely on cross-trial analysis, which carries inherent limitations in patient populations, endpoints, and study duration.

In the 6-month Krystal trial, eszopiclone 3 mg reduced subjective sleep-onset latency (SOL) from a baseline of approximately 50 minutes to 30 minutes (a 20-minute improvement, with placebo improving ~5 minutes). Wake-after-sleep-onset (WASO) improved by roughly 10 to 15 minutes over placebo. The drug sustained efficacy without tolerance development through the full 6-month study period [1]. That finding was notable because Z-drug efficacy data beyond 35 days had been sparse at the time.

In the Herring trials, suvorexant 20 mg reduced polysomnographic SOL by approximately 8 to 10 minutes versus placebo at Month 1 and maintained this through Month 3. Subjective total sleep time (sTST) improved by 16 to 28 minutes depending on the trial and time point. The WASO reduction was 22 to 29 minutes at Month 1 [2]. These numbers suggest a sleep-maintenance advantage, though the populations and measurement methods differ enough to prevent definitive ranking.

A practical distinction: eszopiclone's onset of action is faster (peak plasma concentration within 1 hour) compared with suvorexant (median Tmax of 2 hours). Patients whose primary complaint is difficulty falling asleep may notice a faster subjective effect from eszopiclone. Patients whose problem is staying asleep through the second half of the night may respond better to suvorexant, given its 12-hour half-life and sustained orexin blockade.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline gave both drugs a "WEAK" recommendation for sleep-onset insomnia and sleep-maintenance insomnia, noting that benefits are small relative to placebo across the drug class [4]. The AASM did not rank one above the other.

Side-Effect Profiles Compared

The side-effect picture is where these drugs diverge most sharply, and it is often the reason clinicians consider a switch.

Eszopiclone's most common adverse event is an unpleasant metallic or bitter taste (dysgeusia), occurring in 17% of patients at 2 mg and up to 34% at 3 mg in registration trials [1]. This single side effect drives a substantial portion of discontinuations. Other reported effects include headache (17%), dizziness, dry mouth, and next-morning somnolence. The FDA added a boxed warning in 2019 for complex sleep behaviors (sleepwalking, sleep-driving, engaging in activities while not fully awake) across all Z-drugs, including eszopiclone [5].

Suvorexant's most frequent side effect is next-day somnolence (7% at 20 mg vs. 3% placebo). Sleep paralysis (reported in ~2% of patients), hypnagogic hallucinations, and vivid dreams also appear at a higher rate than with eszopiclone. These are mechanistically predictable because orexin deficiency is the hallmark of narcolepsy Type 1, and blocking orexin receptors can produce narcolepsy-like phenomena at the margins. Suvorexant does not carry the boxed warning for complex sleep behaviors [2].

Neither drug is associated with clinically meaningful respiratory depression at approved doses, making both options reasonable for patients with mild obstructive sleep apnea. A 2020 analysis in the Journal of Clinical Sleep Medicine found that suvorexant did not worsen the apnea-hypopnea index (AHI) in patients with mild-to-moderate OSA (mean AHI 15.8), a finding that may offer an advantage over higher-dose Z-drugs in this population [6].

Abuse Potential and Dependence Risk

Both eszopiclone and suvorexant are DEA Schedule IV substances, but the clinical abuse and dependence story differs between them.

Eszopiclone, as a GABA-A modulator, shares the reinforcing properties of benzodiazepines. In human abuse-liability studies submitted to the FDA, recreational sedative users rated eszopiclone similarly to diazepam on "drug liking" scales at supratherapeutic doses. Tolerance has not been demonstrated in controlled studies lasting up to 6 months [1], though anecdotal dose escalation is reported in clinical practice.

Suvorexant showed lower abuse liability in FDA-reviewed human studies. At doses of 40 mg and 150 mg (2x and 7.5x the maximum recommended dose), it produced less "drug liking" than zolpidem 30 mg in recreational polysubstance users. The FDA clinical pharmacology review for suvorexant noted these findings as supporting a lower abuse profile relative to Z-drugs [7].

This difference matters for patients with a history of substance use disorder or those on chronic opioid therapy. Suvorexant may be the preferred agent when abuse risk must be minimized. The 2023 VA/DoD Clinical Practice Guideline for Management of Chronic Insomnia specifically recommends orexin receptor antagonists over benzodiazepine receptor agonists in patients with comorbid substance use disorders [8].

Rebound Insomnia and Discontinuation Effects

Rebound insomnia, a transient worsening of sleep quality beyond pre-treatment baseline after drug discontinuation, is one of the most common reasons patients feel trapped on a hypnotic.

Eszopiclone's registration program reported mild rebound on the first two nights after abrupt discontinuation of 3 mg doses. In the Krystal 6-month trial, sleep latency on the first night after discontinuation increased to approximately 45 minutes (baseline was ~50 minutes), which did not meet statistical criteria for rebound but left some patients with subjective worsening [1]. Post-marketing experience, however, includes reports of more substantial rebound, particularly after prolonged use at 3 mg.

Suvorexant showed minimal rebound in its Phase III program. In STUDY 029, the night after discontinuation of suvorexant 20 mg, polysomnographic sleep-onset latency and WASO returned to near-baseline without overshooting [2]. This is consistent with the pharmacology: orexin receptors are not downregulated by chronic antagonism in the same way GABA-A receptors can adapt to chronic modulation.

For patients switching because of difficulty stopping eszopiclone, this rebound asymmetry is clinically meaningful. Moving to suvorexant may allow eventual medication discontinuation with a lower risk of withdrawal-driven relapse.

How to Switch from Lunesta to Belsomra (or the Reverse)

There is no FDA-approved protocol, no randomized switching study, and no society guideline that provides an explicit crossover algorithm for these two drugs. The following approach reflects expert consensus and standard clinical practice.

Switching from eszopiclone to suvorexant: Because the two drugs act on different receptor systems, same-night substitution is the most common approach. The patient takes eszopiclone on Night 0, then takes suvorexant instead on Night 1. No taper of eszopiclone is pharmacologically required for patients on 1 mg or 2 mg who have used the drug for fewer than 3 months. For patients on eszopiclone 3 mg for longer than 3 months, a brief 3-to-5-night step-down to 2 mg before switching can reduce the chance of rebound insomnia on the transition night, though many clinicians perform direct substitution without issues.

Expect suvorexant's onset to feel slower on Night 1. Counsel the patient that the drug may take 30 to 60 minutes to produce noticeable drowsiness, compared with eszopiclone's ~15 to 20 minute onset. The full steady-state effect of suvorexant develops over 2 to 3 nights.

Switching from suvorexant to eszopiclone: This transition is simpler. Suvorexant has no meaningful discontinuation syndrome or rebound. The patient can stop suvorexant and start eszopiclone the same night. Begin at the lowest effective eszopiclone dose (1 mg for elderly patients per the FDA label, 2 mg for non-elderly adults) [9].

Key monitoring points during any switch:

• Assess response at 1 week and again at 4 weeks
• Screen for new side effects specific to the incoming drug (taste disturbance if starting eszopiclone; vivid dreams or sleep paralysis if starting suvorexant)
• Continue cognitive behavioral therapy for insomnia (CBT-I) through the transition if it is available, as the AASM 2017 guideline recommends CBT-I as first-line treatment and pharmacotherapy as adjunctive [4]

Drug Interactions Worth Checking Before You Switch

Both drugs rely on CYP3A4 metabolism, which creates overlap in their interaction profiles but also some differences.

Eszopiclone's metabolism involves both CYP3A4 and CYP2E1. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir-boosted HIV regimens) increase eszopiclone exposure and require a dose reduction to 1 mg. The dual metabolic pathway through CYP2E1 provides a partial escape route that limits the magnitude of CYP3A4-mediated interactions [9].

Suvorexant is more vulnerable. It is metabolized primarily through CYP3A4 with no clinically significant alternative pathway. The FDA label contraindicates suvorexant with strong CYP3A4 inhibitors and limits the dose to 5 mg with moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil) [10]. Patients on these medications who need a hypnotic may find eszopiclone the more practical option.

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) can reduce the efficacy of both drugs but will have a larger impact on suvorexant given its single-pathway metabolism.

Alcohol potentiates both drugs. The suvorexant label specifically warns against concomitant alcohol because additive CNS depression compounded with orexin blockade can cause profound next-day impairment. The same applies to eszopiclone, where the FDA label recommends against concomitant ethanol use.

Cost and Insurance Considerations

Formulary placement varies by plan, but broad patterns exist.

Eszopiclone became available as a generic in 2014 after Sepracor's (now Sunovion's) patent expired. A 30-day supply of generic eszopiclone typically costs $10 to $40 with insurance and $30 to $80 at GoodRx-level cash pricing. Most commercial and Medicare Part D plans cover generic eszopiclone at Tier 1 or Tier 2.

Suvorexant (Belsomra) remains brand-only through Merck. A 30-day supply at the 20 mg dose has a wholesale acquisition cost above $400. Many plans place it at Tier 3 (preferred brand) or require prior authorization and step therapy through a generic Z-drug first. Merck's patient savings program can reduce copays for commercially insured patients, but uninsured cash price remains high.

This cost gap is often the practical reason a patient stays on eszopiclone despite tolerability complaints like dysgeusia. Clinicians should note that lemborexant (Dayvigo), another DORA approved in 2019, has a similar cost profile to suvorexant. The newer DORA, suvorexant's class successor, does not yet have a generic either. A 2022 cost-effectiveness analysis in JMCP found that DORAs were not cost-effective compared to generic Z-drugs at a $100,000/QALY threshold unless the patient had contraindications to Z-drug use or a history of complex sleep behaviors [11].

Special Populations

Elderly patients (age 65+): The eszopiclone starting dose is 1 mg in this group due to reduced clearance and heightened fall risk with GABA modulators. The American Geriatrics Society 2023 Beers Criteria lists all Z-drugs as potentially inappropriate in older adults [12]. Suvorexant is not on the Beers list, and its starting dose of 5 mg does not require age-based adjustment (though the FDA recommends 10 mg as a reasonable starting dose for most patients). For elderly patients on eszopiclone who are experiencing falls or confusion, suvorexant may represent a safer alternative.

Patients with hepatic impairment: Both drugs require caution. Eszopiclone should not exceed 2 mg in severe hepatic impairment. Suvorexant has not been studied in severe hepatic impairment and is not recommended [10].

Patients already on CBT-I: Pharmacotherapy can serve as a bridge while behavioral techniques consolidate. A 2012 RCT by Morin et al. in JAMA demonstrated that combining CBT-I with a hypnotic produced superior short-term results, and that tapering the hypnotic while maintaining CBT-I preserved long-term gains [13].